Resources
About Us
Home Report
Store
IVD Reagents Market
IVD Reagents Market Size, Share, Forecast, & Trends Analysis by Type (Antibodies, Proteins, Oligonucleotides, Nucleic Acid Probes) Technology (Immunoassay, Biochemistry, Microbiology, Hematology) Use (Clinical, RUO) End User - Global Forecast to 2031
Report ID:MRHC - 104414 Pages: 389 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursIVD Reagents Market Size & Forecast
The IVD Reagents Market is expected to reach $79.76 billion by 2031, at a CAGR of 5.3% from 2024 to 2031. The growth of the IVD reagents market can be attributed to several factors, including the increasing prevalence of infectious diseases, increasing funding for research activities, the rising adoption of advanced diagnostic technologies, the growth in proteomics & genomics research studies, and the growing number of clinical laboratories offering advanced diagnostic testing menus. Moreover, emerging economies and the growing demand for protein therapeutics & personalized medicines are expected to offer growth opportunities for the players operating in this market.
IVD Reagents Market Growth Drivers
Increasing Prevalence of Infectious Diseases
Infectious diseases are mainly caused by organisms such as bacteria, viruses, fungi, and parasites. Some infectious diseases get transmitted from person to person or through bites from insects or animals. The burden of infectious diseases has increased globally, driving the demand for safe and effective diagnostic assays. Hence, the demand for IVD reagents is expected to grow with the increased utilization of diagnostic assays. The following statistics indicate the increased prevalence of infectious diseases:
- In 2021, 39 million people had HIV globally, of which 1.5 million were children. There were 20.8 million (53%) people with HIV in eastern and southern Africa, 5 million (13%) in western and central Africa, 6.5 million (15%) in Asia and the Pacific, and 2.3 million (5%) in Western and Central Europe and North America.
- According to an article published in the United Nations digital magazine Africa Renewal in July 2022, the risk of outbreaks caused by zoonotic pathogens such as the Ebola & monkeypox viruses that originate in animals and infect humans is rising. There has been a 63.0% increase in the number of zoonotic disease outbreaks in Africa from 2012–2022 compared to 2001– 2011 (Source: WHO).
- According to the WHO, about 1.6 million people died from tuberculosis in 2021. The disease was the 13th leading cause of death globally. In 2021, there were 10.6 million new cases of tuberculosis, of which 3.4 million were women and 1.2 million were children. The burden of drug-resistant TB (DR-TB) increased by 3% between 2020 and 2021, with 450,000 new cases of rifampicin-resistant TB (RR-TB) recorded in 2021.
Thus, the increasing prevalence of infectious diseases is expected to boost the need for diagnosis, driving the demand for IVD reagents.
Click here to: Get a Free Sample Copy of this report
Increase in Proteomics and Genomics Research Studies
In recent years, there has been a significant increase in proteomics and genomics-based research studies driven by technological advancements and the need to understand the genetic and molecular bases of various diseases. Proteomics and genomics are employed to identify proteins and genes, their structures, functions, and modifications across various research areas, particularly in medical research, drug discovery, and diagnostics. Researchers are currently utilizing multiple antibodies, including polyclonal, monoclonal, recombinant, and mono-specific antibodies, due to their high target specificity and strong affinity for target molecules.
Traditionally, proteomics and genomics studies were conducted using conventional Sanger sequencing technology, which sequenced and analyzed single genes, amplicon targets, genomic fragments, and short tandem repeats. However, according to the National Human Genome Research Institute, Sanger sequencing can produce inaccurate results, offer low throughput, and be time-consuming. Consequently, it has recently been largely replaced by Next-Generation Sequencing (NGS).
NGS can analyze 100 genes simultaneously, requires a lower amount of input material, and is cost-effective. Sanger sequencing costs about USD 500 per 1,000 bases, while NGS costs around USD 0.50 per 1,000 bases. This significant cost difference has prompted researchers to adopt more sophisticated and specific techniques. Advanced genomics and proteomics methods leverage antibody-based research for biomarker identification and drug development. For instance, the monoclonal antibody inhibitor trastuzumab (ErbB2, HER-2) has been used as a monotherapy in women with HER-2 overexpressing metastatic breast cancer.
Thus, the transition to new genomics and proteomics techniques is enhancing the precision and efficiency of research, supporting advances in biomarker identification and drug development.
IVD Reagents Market Trends
Growing Use of IVD Reagents in DNA Sequencing & Next-generation Sequencing
DNA sequencing determines a DNA molecule's precise order of nucleotides (adenine, guanine, cytosine, and thymine). DNA sequencing is a fundamental technique in molecular biology, genetics, and genomics and has revolutionized many areas of biological research. Next-generation sequencing (NGS) is a large-scale DNA high-throughput technology that can parallel sequence millions of small DNA fragments. Hence, the technology is also referred to as massively parallel sequencing. It can sequence entire genomes, including all 22,000 coding genes or small numbers of individual genes. NGS has well-known applications in various life sciences, such as oncology, forensic sciences, functional genomics, transcriptomics, medicine, and evolutionary biology. NGS has enabled the analysis of multiple genome regions in one single reaction and is a cost-effective and efficient tool in investigating patients with Mendelian diseases. Consequently, NGS methods have provided a great impetus to discovering genetic aberrations and their establishment as prognostic and predictive markers of diseases.
In addition, clinical laboratories are increasingly adopting NGS testing, which requires IVD reagents as a standard for diagnosing hereditary disorders, such as phenylketonuria, congenital myopathy, cystic fibrosis, and periodic paralysis syndromes. Further, the adoption of NGS-based IVD tests, which require IVD reagents, is likely to increase in the future, thereby broadening the adoption of IVD reagents detecting a wide array of diseases.
Additionally, the continuous advancements in DNA sequencing have led to the emergence of fourth-generation sequencing, which incorporates nanopore technology into single-molecule sequencing (SMS). This technology performs real-time sequencing without amplification and repeated cycles by eliminating synthesis. The fourth-generation sequencing, also known as in situ sequencing technology, has widened the applications of DNA sequencing, which requires IVD reagents to identify the order of nucleotides in fixed cells and tissues.
IVD Reagents Market Opportunity
Growing Demand for Protein Therapeutics and Personalized Medicines
Protein therapeutics is a branch of medicine that can serve patients needing novel therapies. Advances in protein-engineering technologies (such as mass spectrometry), molecular genetics, and production technologies are key drivers of protein therapeutic practices. Drug developers are exploiting the functional characteristics of desired proteins to maintain and enhance product safety or efficacy. The fastest-growing class of therapeutic proteins is an antibody that includes bispecific mAbs, multispecific fusion proteins, and mAbs conjugated with small-molecule drugs designed to treat cancers, immune disorders, infections, and other diseases.
According to a research article published in F1000Research, recent advances in protein purification technologies and expression systems have increased the production of therapeutic peptides while maintaining product safety or efficacy or both at the same time. Further, government initiatives supporting the development of personalized medicines (which largely include monoclonal antibodies) have boosted antibody production.
In March 2020, scientists in South Africa developed a new antibody technology for precision medicine. A group of researchers from the University of Cape Town’s Medical Biotechnology and Immunotherapy Research Unit published a paper explaining how certain proteins based on antibodies, called SNAP-tag fusion proteins, may help reduce the cost and time needed to develop new personalized therapies. The fact that antibodies have these specific targets is important in developing targeted therapies. Scientists can generate new protein combinations for various applications by rearranging genetic material such as antibody genes. An example of precision medicine is using antibody technologies to identify breast cancer patients treated with trastuzumab.
Thus, the increasing demand for therapeutic proteins and personalized medicines and the increase in approvals are expected to create growth opportunities for the players operating in the IVD reagents market.
Growth in Emerging Economies
Emerging economies in Asia-Pacific and Latin America are expected to offer market growth opportunities due to the rising demand for antibodies and oligonucleotides, increasing funding for R&D, rising healthcare expenditures, and ongoing developments in healthcare infrastructure. Countries such as China, India, Brazil, and Mexico have significantly contributed to revenue generation for various stakeholders in this market, mainly due to the increasing number of research institutes, clinical and diagnostic laboratories, and pharmaceutical and biopharmaceutical companies. Additionally, growth in public and private R&D funding and contract research supports market growth in these countries.
According to the United Nations, Asia-Pacific is witnessing rapid growth in its aging population. In 2022, 12.7% of the population in Eastern and Southeastern Asia was aged 65 years or older, and the percentage is projected to increase to 25.7% by 2050. Thus, the prevalence of age-related disorders, such as cancer, is rising in Asia-Pacific.
Moreover, the increasing healthcare expenditures in emerging economies from Asia-Pacific and South and Central America are enabling physicians to diagnose a wide range of diseases through advanced testing and examination techniques requiring specific reagents. Most market players are focused on emerging economies due to the increasing prevalence of infectious and chronic diseases.
IVD Reagents Market Analysis: Key Findings
By Type: In 2024, the Antibodies Segment to Dominate the IVD Reagents Market
Based on types, the market is segmented into antibodies, purified proteins and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. In 2024, the antibodies segment is expected to account for the largest share of 22.1% of the IVD reagents market. Antibodies are glycoproteins produced by plasma cells in response to an antigen stimulus. These antibodies are highly specific to target molecules. Antibodies are necessary reagents for research and in vitro diagnostic (IVD) applications and specifically bind to a specific biomolecule or a protein of interest. The large share of the segment is attributed to factors such as inherent specificity, high throughput, high sensitivity, and low cost, which drive the growth of this technology segment. Further, the increasing use of immunoassays in POC & infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests also contribute to the large share.
By Technology: In 2024, the Immunoassay/Immunochemistry Segment to Dominate the IVD Reagents Market
Based on technologies, the market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other IVD technologies. In 2024, the immunoassay/immunochemistry segment is expected to account for the largest share of 30.8% of the IVD reagents market. Immunoassay/immunochemistry is a bioanalytical method in which the quantitation of the analyte depends on the reaction of an antigen and antibody. The large share of the segment is attributed to factors such as the increasing use of immunoassays in POC and infectious disease testing, the development of novel tests, the increasing usage of miniaturized devices, and the rising demand for immunoassay-based tests.
By Use: In 2024, the Clinical Use Segment to Dominate the IVD Reagents Market
Based on uses, the market is segmented into clinical use, research use only (RUO), and analyte-specific reagents (ASR). In 2024, the clinical use segment is expected to account for the largest share of the IVD reagents market. IVD reagents are critical components in clinical laboratories. Without these reagents, these laboratories cannot generate the information required for patient diagnosis, monitoring, and treatment. Chemical, biochemical, and immunochemical reagents are the types of reagents used in clinical applications. Initiatives by manufacturers for developing advanced IVD clinical applications, ongoing clinical trials, and exemption from the investigational device (IDE) requirements are the factors contributing to the largest share of this segment.
By End User: the IVD Manufacturers Segment to Dominate the IVD Reagents Market
Based on end users, the market is segmented into IVD manufacturers, reference laboratories, academic institutes & research laboratories, and hospital laboratories. In 2024, the IVD manufacturers segment is expected to account for the largest share of 35% of the IVD reagents market. In-vitro diagnostic (IVD) reagents are critical components in clinical and special chemistry testing laboratories. These labs generate the information required for patient diagnosis, monitoring, and treatment using IVD reagents. The large share of the segment is attributed to factors such as increasing demand for innovative products, growing incidence of chronic diseases, increasing demand for pharmaceutical & biopharmaceutical products from emerging countries, and initiatives undertaken by IVD manufacturers.
Geographical Analysis
By Geography: North America to Dominate the IVD Reagents Market
In 2024, North America is expected to account for the largest share of 37.7% of the IVD reagents market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The largest share of the segment is primarily due to the growing awareness regarding early disease diagnosis, expanding healthcare sector, high prevalence of infectious and chronic diseases, rising funding activities coupled with the development of novel advanced diagnostic technologies, and growing adoption of advanced diagnostic products.
However, Asia-Pacific is slated to register the highest CAGR of 7.8% during the forecast period. This is attributed to factors such as rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, the presence of key IVD reagent companies in countries like China, India, Singapore, and South Korea, and government investments in research and development activities. Furthermore, the need to manage the growing burden of infectious diseases, growing accessibility to healthcare services & advanced products, growing income levels of the middle-class population, and increasing number of hospitals and clinics contribute to the growth of this market.
IVD Reagents Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last 3–4 years. Some of the key players operating in the IVD reagents market are Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), BioTechne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.).
IVD Reagents Industry Overview: Latest Developments from Key Industry Players
- In April 2023, Beckman Coulter, Inc. received In Vitro Diagnostic Medical Devices Regulation (IVDR) certification to help prepare labs for IVDR.
- In April 2022, Becton, Dickinson and Company launched AI-based D Horizon RealYellow 586 Reagents for flow cytometry. These reagents help researchers to increase improved data resolution and larger insights from samples compared to traditional fluorochromes.
- In January 2022, Beckman Coulter, Inc. received In Vitro Diagnostic Medical Devices Regulation (IVDR) certification for more than 200 flow cytometry reagents developed and manufactured at their Marseille, France facility.
IVD Reagents Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
389 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
5.3% |
|
Market Size (Value) |
USD 79.76 Billion by 2031 |
|
Segments Covered |
By Type
By Technology
By Use
By End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa |
|
Key Companies |
Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), BioTechne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.) |
Key questions answered in the IVD reagents market report:
This market study covers the market sizes & forecasts of the IVD reagents based on type, technology, use, end user, and geography. It also provides the value analysis of various segments and sub-segments of the global IVD reagents market at country levels.
The IVD reagents market is projected to reach $79.76 billion by 2031, at a CAGR of 5.3% during the forecast period.
The antibodies segment is expected to account for the largest share of the market in 2024. The large market share of this segment is attributed to the advantages offered by the segment, like the inherent specificity, high throughput, high sensitivity, and low cost are driving the growth of this technology segment. Further, the increasing use of immunoassays in POC & infectious disease testing, the development of novel tests, and the rising demand for immunoassay-based tests are the factors contributing to the largest share of this segment.
The growth of the IVD reagents market is driven by the increasing prevalence of infectious diseases, increasing funding for research activities, the rising adoption of advanced diagnostic technologies, the growth in proteomics and genomics research studies, and the growing number of clinical laboratories offering advanced diagnostic testing menus. Additionally, emerging economies and the growing demand for protein therapeutics and personalized medicines are expected to offer significant market growth opportunities.
The key players profiled in the IVD reagents market report are Thermo Fisher Scientific (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abcam plc (U.K.), Hologic Inc. (U.S.), InBios International, Inc. (U.S.), SDIX, LLC (U.S.), Bio Techne Corporation (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), Sino Biological Inc. (China), Oy Medix Biochemica Ab (Finland), QIAGEN N.V. (Netherlands), and Beckman Coulter, Inc. (U.S.).
In 2024, emerging economies, such as China and India, are expected to provide significant growth opportunities for market players due to the increasing government research and development spending in these countries. Furthermore, factors such as the increasing incidence of chronic disorders, increasing government focus on R&D of biopharmaceuticals, growing number of healthcare facilities, availability of advanced technologies, and growing investments for developing personalized medicines are driving the demand for IVD reagents.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Increasing Prevalence of Infectious Diseases
4.2.1.2. Increasing Funding for Research Activities
4.2.1.3. Growth in Proteomics and Genomics Research Studies
4.2.1.4. Growing Number of Clinical Laboratories Offering Advanced Diagnostic Testing Menus
4.2.2. Restraints
4.2.2.1. Stringent Regulations for Antigen-Specific Reagents
4.2.3. Opportunities
4.2.3.1. Growing Demand for Protein Therapeutics and Personalized Medicines
4.2.3.2. Emerging Economies
4.2.4. Challenges
4.2.4.1. High Costs of Reagents and the Unfavorable Reimbursement Scenario
4.2.5. Factor Analysis
4.3. Regulatory Analysis
4.3.1. U.S.
4.3.2. Canada
4.3.3. Europe
4.3.4. China
4.3.5. Japan
4.3.6. India
4.3.7. Latin America
4.3.8. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Buyers
4.4.2. Bargaining Power of Suppliers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Pricing Analysis
5. In Vitro Diagnostic (IVD) Reagents Market Assessment—by Type
5.1. Overview
5.2. Antibodies
5.2.1. Antibodies Market, by Type
5.2.1.1. Monoclonal Antibodies
5.2.1.2. Polyclonal Antibodies
5.2.2. Antibodies Market, by Target
5.2.2.1. Cluster of Differentiation (CD)
5.2.2.2. T-Cell Receptor (TCR)
5.2.2.3. Epidermal Growth Factor Receptor (EGFR)
5.2.2.4. Other Targets
5.3. Purified Proteins and Peptides
5.4. Oligonucleotides
5.5. Nucleic Acid Probes
5.6. Other IVD Reagents
6. In Vitro Diagnostic (IVD) Reagents Market Assessment—by Technology
6.1. Overview
6.2. Immunoassay/Immunochemistry
6.2.1. Enzyme-Linked Immunosorbent Assays (ELISA) and Enzyme-Linked Immunospot Assays (ELISpot)
6.2.2. Lateral Flow Assays/Rapid Tests
6.2.3. Western Blotting
6.2.4. Immunofluorescence (IF)
6.2.5. Functional Assays
6.2.6. Immunoprecipitation
6.2.7. Other Immunoassay Technologies
6.3. Biochemistry/Clinical Chemistry
6.4. Molecular Diagnostics
6.4.1. Polymerase Chain Reaction (PCR)
6.4.2. Hybridization
6.4.3. Isothermal Nucleic Acid Amplification Technology
6.4.4. DNA Sequencing & Next-generation Sequencing
6.4.5. Microarrays
6.4.6. Other Molecular Diagnostic Technologies
6.5. Microbiology
6.6. Hematology
6.7. Coagulation/Hemostasis
6.8. Urinalysis
6.9. Other IVD Technologies
7. In Vitro Diagnostic Reagents Market Assessment—by Use
7.1. Overview
7.2. Clinical Use
7.3. Research Use Only (RUO)
7.4. Analyte-Specific Reagents (ASR)
8. In Vitro Diagnostic Reagents Market Assessment—by End User
8.1. Overview
8.2. IVD Manufacturers
8.3. Reference Laboratories
8.4. Academic Institutes & Research Laboratories
8.5. Hospital Laboratories
9. In Vitro Diagnostic Reagents Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Switzerland
9.3.7. Netherlands
9.3.8. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. South Korea
9.4.5. Australia
9.4.6. Singapore
9.4.7. Rest of Asia-Pacific
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Competitive Benchmarking
10.3. Competitive Dashboard
10.3.1. Industry Leaders
10.3.2. Market Differentiators
10.3.3. Vanguards
10.3.4. Emerging Companies
10.4. Market Share Analysis (2023)
10.4.1. Thermo Fisher Scientific (U.S.)
10.4.2. Merck KGaA (Germany)
10.4.3. Becton, Dickinson and Company (U.S.)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Thermo Fisher Scientific Inc.
11.2. Becton, Dickinson and Company
11.3. Bio-Rad Laboratories, Inc.
11.4. Agilent Technologies, Inc.
11.5. QIAGEN N.V.
11.6. Merck KGaA
11.7. Beckman Coulter, Inc. (A subsidiary of Danaher Corporation)
11.8. Hologic, Inc.
11.9. Abcam Plc.
11.10. Bio-Techne Corporation
11.11. Bio-Synthesis Inc.
11.12. Raybiotech, Inc.
11.13. SDIX, LLC. (A subsidiary of Origene Technologies, Inc.)
11.14. Sino Biological Inc.
11.15. Oy Medix Biochemica Ab
11.16. InBios International, Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Percentage of the Population Aged 65 Years or Above, by Region, 2022 Vs 2030 Vs 2050
Table 2 Human Immunodeficiency Virus (HIV) Statistics, 2022
Table 3 Health Expenditure, by Country
Table 4 Regulatory Authorities Governing In Vitro Diagnostics, by Country
Table 5 China: IVD Reagents Classification
Table 6 IVD Reagent Registration/Filing in China
Table 7 IVD Reagents Price List
Table 8 Global In-Vitro Diagnostic Reagents Market, by Type, 2022–2031 (USD Million)
Table 9 Global Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Antibodies Market, by Type, 2022–2031 (USD Million)
Table 11 Key Companies Offering Monoclonal Antibodies for IVD
Table 12 Global Monoclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Key Companies Offering Polyclonal Antibodies for IVD
Table 14 Global Polyclonal Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Antibodies Market, by Target, 2022–2031 (USD Million)
Table 16 Key Companies Offering CD Antibodies for IVD
Table 17 Global CD Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Key Companies Offering TCR Antibodies
Table 19 Global TCR Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Key Companies Offering EGFR Antibodies
Table 21 Global EGFR Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Other Target Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Key Companies Offering Purified Proteins
Table 24 Global Purified Proteins and Peptides Market, by Country/Region, 2022–2031 (USD Million)
Table 25 Key Companies Offering Oligonucleotides
Table 26 Global Oligonucleotides Market, by Country/Region, 2022–2031 (USD Million)
Table 27 Key Companies Offering Nucleic Acid Probes
Table 28 Global Nucleic Acid Probes Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Other IVD Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 30 Global In-Vitro Diagnostic Reagents Market, by Technology, 2022–2031 (USD Million)
Table 31 Global IVD Reagents Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 32 Global IVD Reagents Market for Immunoassay/Immunochemistry, by Country/Region, 2022–2031 (USD Million)
Table 33 Global IVD Reagents Market for ELISA and ELISpot, by Country/Region, 2022–2031 (USD Million)
Table 34 Global IVD Reagents Market for Lateral Flow Assays/Rapid Tests, by Country/Region, 2022–2031 (USD Million)
Table 35 Global IVD Reagents Market for Western Blotting, by Country/Region, 2022–2031 (USD Million)
Table 36 Global IVD Reagents Market for Immunofluorescence, by Country/Region, 2022–2031 (USD Million)
Table 37 Global IVD Reagents Market for Functional Assays, by Country/Region, 2022–2031 (USD Million)
Table 38 Global IVD Reagents Market for Immunoprecipitation, by Country/Region, 2022–2031 (USD Million)
Table 39 Global IVD Reagents Market for Other Technologies, by Country/Region, 2022–2031 (USD Million)
Table 40 Global IVD Reagents Market for Biochemistry/Clinical Chemistry, by Country/Region, 2022–2031 (USD Million)
Table 41 Global IVD Reagents Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 42 Global IVD Reagents Market for Molecular Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 43 Global IVD Reagents Market for Polymerase Chain Reaction, by Country/Region, 2022–2031 (USD Million)
Table 44 Global IVD Reagents Market for Hybridization, by Country/Region, 2022–2031 (USD Million)
Table 45 Global IVD Reagents Market for Isothermal Nucleic Acid Amplification Technology, by Country/Region, 2022–2031 (USD Million)
Table 46 Global IVD Reagents Market for DNA Sequencing & Next-Generation Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 47 Global IVD Reagents Market for Microarrays, by Country/Region, 2022–2031 (USD Million)
Table 48 Global IVD Reagents Market for Other Molecular Diagnostics Technologies, by Country/Region, 2022–2031 (USD Million)
Table 49 Global IVD Reagents Market for Microbiology, by Country/Region, 2022–2031 (USD Million)
Table 50 Global IVD Reagents Market for Hematology, by Country/Region, 2022–2031 (USD Million)
Table 51 Global IVD Reagents Market for Coagulation/Hemostasis, by Country/Region, 2022–2031 (USD Million)
Table 52 Global IVD Reagents Market for Urinalysis, by Country/Region, 2022–2031 (USD Million)
Table 53 Global IVD Reagents Market for Other IVD Technologies, by Country/Region, 2022–2031 (USD Million)
Table 54 Global In-Vitro Diagnostic Reagents Market, by Use, 2022–2031 (USD Million)
Table 55 Global Clinical Use IVD Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 56 Global Research Use Only (RUO) IVD Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 57 Global Analyte-Specific Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 58 Global In-Vitro Diagnostic Reagents Market, by End User, 2022–2031 (USD Million)
Table 59 Global IVD Reagents Market for IVD Manufacturers, by Country/Region, 2022–2031 (USD Million)
Table 60 Global IVD Reagents Market for Reference Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 61 Global IVD Reagents Market Size for Academic Institutes & Research Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 62 Global IVD Reagents Market Size for Hospital Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 63 Global In Vitro Diagnostic Reagents Market, by Country/Region, 2022—2031 (USD Million)
Table 64 North America: In Vitro Diagnostic Reagents Market, by Country, 2022—2031 (USD Million)
Table 65 North America: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 66 North America: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 67 North America: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 68 North America: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 69 North America: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 70 North America: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 71 North America: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 72 North America: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 73 U.S.: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 74 U.S.: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 75 U.S.: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 76 U.S.: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 77 U.S.: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 78 U.S.: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 79 U.S.: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 80 U.S.: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 81 Canada: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 82 Canada: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 83 Canada: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 84 Canada: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 85 Canada: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 86 Canada: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 87 Canada: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 88 Canada: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 89 Europe: In Vitro Diagnostic Reagents Market, by Country, 2022—2031 (USD Million)
Table 90 Europe: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 91 Europe: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 92 Europe: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 93 Europe: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 94 Europe: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 95 Europe: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 96 Europe: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 97 Europe: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 98 Germany: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 99 Germany: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 100 Germany: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 101 Germany: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 102 Germany: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 103 Germany: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 104 Germany: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 105 Germany: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 106 France: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 107 France: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 108 France: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 109 France: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 110 France: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 111 France: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 112 France: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 113 France: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 114 U.K.: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 115 U.K.: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 116 U.K.: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 117 U.K.: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 118 U.K.: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 119 U.K.: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 120 U.K.: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 121 U.K.: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 122 Italy: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 123 Italy: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 124 Italy: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 125 Italy: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 126 Italy: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 127 Italy: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 128 Italy: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 129 Italy: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 130 Spain: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 131 Spain: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 132 Spain: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 133 Spain: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 134 Spain: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 135 Spain: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 136 Spain: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 137 Spain: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 138 Switzerland: Number of New Cancer Cases (2020 Vs 2030)
Table 139 Switzerland: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 140 Switzerland: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 141 Switzerland: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 142 Switzerland: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 143 Switzerland: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 144 Switzerland: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 145 Switzerland: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 146 Switzerland: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 147 Netherlands: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 148 Netherlands: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 149 Netherlands: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 150 Netherlands: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 151 Netherlands: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 152 Netherlands: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 153 Netherlands: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 154 Netherlands: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 155 Rest of Europe: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 156 Rest of Europe: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 157 Rest of Europe: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 158 Rest of Europe: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 159 Rest of Europe: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 160 Rest of Europe: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 161 Rest of Europe: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 162 Rest of Europe: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 163 Asia–Pacific: In Vitro Diagnostic Reagents Market, by Country, 2022—2031 (USD Million)
Table 164 Asia–Pacific: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 165 Asia–Pacific: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 166 Asia–Pacific: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 167 Asia–Pacific: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 168 Asia–Pacific: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 169 Asia–Pacific: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 170 Asia–Pacific: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 171 Asia–Pacific: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 172 China: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 173 China: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 174 China: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 175 China: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 176 China: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 177 China: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 178 China: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 179 China: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 180 Japan: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 181 Japan: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 182 Japan: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 183 Japan: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 184 Japan: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 185 Japan: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 186 Japan: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 187 Japan: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 188 India: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 189 India: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 190 India: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 191 India: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 192 India: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 193 India: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 194 India: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 195 India: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 196 South Korea: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 197 South Korea: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 198 South Korea: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 199 South Korea: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 200 South Korea: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 201 South Korea: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 202 South Korea: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 203 South Korea: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 204 Australia: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 205 Australia: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 206 Australia: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 207 Australia: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 208 Australia: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 209 Australia: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 210 Australia: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 211 Australia: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 212 Singapore: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 213 Singapore: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 214 Singapore: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 215 Singapore: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 216 Singapore: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 217 Singapore: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 218 Singapore: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 219 Singapore: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 220 Rest of Asia-Pacific: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 221 Rest of Asia-Pacific: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 222 Rest of Asia-Pacific: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 223 Rest of Asia-Pacific: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 224 Rest of Asia-Pacific: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 225 Rest of Asia-Pacific: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 226 Rest of Asia-Pacific: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 227 Rest of Asia-Pacific: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 228 Latin America: In Vitro Diagnostic Reagents Market, by Country, 2022—2031 (USD Million)
Table 229 Latin America: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 230 Latin America: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 231 Latin America: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 232 Latin America: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 233 Latin America: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 234 Latin America: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 235 Latin America: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 236 Latin America: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 237 Brazil: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 238 Brazil: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 239 Brazil: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 240 Brazil: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 241 Brazil: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 242 Brazil: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 243 Brazil: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 244 Brazil: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 245 Mexico: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 246 Mexico: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 247 Mexico: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 248 Mexico: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 249 Mexico: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 250 Mexico: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 251 Mexico: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 252 Mexico: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 253 People (20-79 Years) with Diabetes in Argentina, Colombia, and Chile (In Thousands)
Table 254 Rest of Latin America: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 255 Rest of Latin America: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 256 Rest of Latin America: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 257 Rest of Latin America: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 258 Rest of Latin America: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 259 Rest of Latin America: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 260 Rest of Latin America: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 261 Rest of Latin America: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
Table 262 Middle East & Africa: In Vitro Diagnostic Reagents Market, by Technology, 2022—2031 (USD Million)
Table 263 Middle East & Africa: Immunoassay/Immunochemistry Market, by Type, 2022—2031 (USD Million)
Table 264 Middle East & Africa: Molecular Diagnostics Market, by Type, 2022—2031 (USD Million)
Table 265 Middle East & Africa: In Vitro Diagnostic Reagents Market, by Type, 2022—2031 (USD Million)
Table 266 Middle East & Africa: Antibodies Market, by Type, 2022—2031 (USD Million)
Table 267 Middle East & Africa: Antibodies Market, by Target, 2022—2031 (USD Million)
Table 268 Middle East & Africa: In Vitro Diagnostic Reagents Market, by Use, 2022—2031 (USD Million)
Table 269 Middle East & Africa: In Vitro Diagnostic Reagents Market, by End User, 2022—2031 (USD Million)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global IVD Reagents Market, by Type, 2024 Vs.2031 (USD Million)
Figure 8 Global IVD Reagents Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 9 Global IVD Reagents Market, by Use, 2024 Vs. 2031 (USD Million)
Figure 10 Global IVD Reagents Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Global IVD Reagents Market, by Geography
Figure 12 Impact Analysis: IVD Reagents Market
Figure 13 U.S.: Share of Medical and Health R&D Expenditure, by Organization Type, 2020
Figure 14 Global Pharmaceutical R&D Expenditure, 2016–2024 (USD Billion)
Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030
Figure 16 USFDA Regulatory Pathways for IVD Reagents
Figure 17 Eu Regulatory Pathway - IVD r 2017/746
Figure 18 Porter’s Five Forces Analysis
Figure 19 Global In-Vitro Diagnostic Reagents Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 20 Global In-Vitro Diagnostic Reagents Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 21 Global In-Vitro Diagnostic Reagents Market, by Use, 2024 Vs. 2031 (USD Million)
Figure 22 Global In-Vitro Diagnostic Reagents Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 23 Global In Vitro Diagnostic Reagents Market, by Region, 2024 Vs. 2031 (USD Million)
Figure 24 North America: Healthcare Expenditure (% of GDP), 2015—2020
Figure 25 North America: IVD Reagents Market Snapshot
Figure 26 Canada: Number of People Aged 65 and above, 2018—2022 (In Million)
Figure 27 Europe: In Vitro Diagnostic Reagents Market Snapshot
Figure 28 France: Number of People Aged 65 Years and above, 2017—2022 (Millions)
Figure 29 U.K.: Number of Cancer Cases, 2020—2040 (In Millions)
Figure 30 U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018—2020 (In Thousands)
Figure 31 Italy: Ovarian Cancer Cases (2020—2040)
Figure 32 Spain: Number of HIV Tests Performed in Catalonia (Spain), 2017—2021
Figure 33 Switzerland: Number of People Aged 65 Years and above, 2018—2022
Figure 34 Netherlands: Number of People Aged 65 Years and above, 2017—2022
Figure 35 Rest of Europe: Healthcare Expenditure (2015 Vs 2020)
Figure 36 Asia-Pacific: In Vitro Diagnostic Reagents Market Snapshot
Figure 37 Japan: Percentage Share of The Geriatric Population (Aged 65 Years and above) (2018—2022)
Figure 38 India: Number of People Aged 65 Years and above, 2018-2022 (% of Total Population)
Figure 39 Latin America: Number of People Aged 65 Years and above, 2015-2022 (In Millions)
Figure 40 Latin America: In Vitro Diagnostic Reagents Market Snapshot
Figure 41 Brazil: Prevalence of Diabetes, 2000—2045, (In Thousands)
Figure 42 IVD Reagents Market: Competitive Benchmarking (Based on Type)
Figure 43 IVD Reagents Market: Competitive Benchmarking (Based on Use)
Figure 44 IVD Reagents Market: Competitive Benchmarking (Based on Geography)
Figure 45 Competitive Dashboard: IVD Reagents Market
Figure 46 Global IVD Reagents Market Share Analysis, by Key Players, 2023 (%)
Figure 47 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 48 Becton, Dickinson and Company: Financial Snapshot (2023)
Figure 49 Bio-Rad Laboratories, Inc.: Financial Snapshot (2023)
Figure 50 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 51 QIAGEN N.V.: Financial Snapshot (2023)
Figure 52 Merck KGaA: Financial Snapshot (2023)
Figure 53 Danaher Corporation: Financial Snapshot (2023)
Figure 54 Hologic, Inc.: Financial Snapshot (2023)
Figure 55 Abcam Plc.: Financial Snapshot (2023)
Figure 56 Bio-Techne Corporation: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Biochemical Reagents Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Aug-2024
Chromatography Reagents Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
Middle East IVD Market - Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
Asia-Pacific IVD Market - Opportunity Analysis and Industry Forecasts (2024-2031)
Published Date: Jan-2024
